Atlas Trials

A Clinical Trial to Evaluate the Reversibility of Abacavir/Lamivudine/Dolutegravir CNS-Related Neurotoxicity After Switching to Tenofovir/Alafenamide/Emtricitabine/Darunavir/Cobicistat (TAF/FTC/DRV/c)

Clinical trial NCT03685500 · COMPLETED

Trial details

NCT number
NCT03685500
Sponsor
Fundacion SEIMC-GESIDA
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
HIV Infections
Start date
2018-12-04
Primary completion
2020-06-25
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.